Journal of Genetic Disorders & Genetic ReportsISSN: 2327-5790

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Screening of Genetic Mutations in GBA1, GIGYF2 and VPS35 in Parkinson Disease Patients from India

Background: Mutations in Glucocerebrosidase gene (GBA1) has long been identified as a genetic risk factor for Parkinson disease (PD) in various ethnic populations such as Chinese, Taiwanese, Canadian, Caucasian, Hungarian, Ashkenazi Jewish etc. However, so far no report exists on the role of GBA1 in the PD patients in Indian population. The present study has been designed to assess the frequency of two common mutations in GBA1 (p.L444P and p.N370S) along with two other recently reported mutations: (i) p.R610G in Growth factor Receptor Binding protein 10 interacting GYF protein 2 (GIGYF2) and (ii) p.D620N in Vacuolar protein shorting homolog 35 (VPS35) those were identified by nextgeneration sequencing in Spanish and Swiss/Australian PD families respectively, in Indian PD patient cohort.

Methods: A total of 114 clinically diagnosed PD patients including 2 familial cases and 120 ethnically matched healthy controls were enrolled for this study. GBA1 mutations were screened by PCR-RFLP and other two mutations in GIGYF2 and VPS35 were analyzed by direct DNA sequencing of the corresponding exons containing the selected mutations.

Results: Higher frequency of p.L444P mutation in GBA1 was found in PD patient cohort (3.51%) compared to controls (0%) (p=0.0548; OR=9.81, 95% CI 0.52-184.38). This frequency was higher in earlyonset PD group (6.06%) than that of Late onset PD group (2.46%) (p=0.2563). None of the PD patients posses any of the three rest mutations indicating it’s rarity in this population.

Conclusion: The present study concludes that the carriers of p.L444P mutation in GBA1 associated with Gaucher’s Disease (GD) are at an increased risk (OR=9.81, 95% CI 0.52-184.38) of developing PD in north-India irrespective of age of disease onset.

Special Features

Full Text

View

Track Your Manuscript

Media Partners

GET THE APP